Chronic Lymphocytic Leukemia Clinical Trials

70 studies are recruiting for chronic lymphocytic leukemia in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies, page 3

1. Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia

   This study will evaluate fixed-duration therapy with pirtobrutinib and obinutuzumab given over 12 cycles (approximately 1 year) as first-line treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL or SLL).

   Stage

   Phase 2

   Ages

   18 and older

   Site

   New England Cancer Specialists, Scarborough, Maine

   Locations

   4 in total

   Run by

   Inhye Ahn

   See if you can join NCT06333262 on ClinicalTrials.gov

2. Anti-pneumococcal Vaccine Strategy in Patients With Chronic Lymphocytic Leukemia

   This phase II trial compares the effect of initial vaccination (PCV20 followed by PSV23) with yearly vaccinations of PSV23 to the standard 5 year vaccination in patients with chronic lymphocytic leukemia. At present chronic lymphocytic leukemia patients are poorly protected by anti-pneumococcal vac…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Ohio State University Comprehensive Cancer Center, Columbus, Ohio

   Run by

   Seema Bhat

   See if you can join NCT05417165 on ClinicalTrials.gov

3. Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation

   This research is being done to evaluate Glofitamab by itself or in combination with Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab as possible treatments for Chronic Lymphocytic Leukemia (CLL) that has transformed into Richter's Transformation (RT). The names of the study drugs involved in thi…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Winship Cancer Institute at Emory University, Atlanta, Georgia

   Locations

   5 in total

   Run by

   Christine Ryan

   See if you can join NCT06043674 on ClinicalTrials.gov

4. Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL

   This is a randomized Phase II study of intermittent versus continuous venetoclax therapy with Acalabrutinib in previously untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Cincinnati, Cincinnati, Ohio

   Run by

   Zulfa Omer

   See if you can join NCT07014917 on ClinicalTrials.gov

5. Study of Epcoritamab as a Consolidation Therapy in CLL/SLL

   This is a phase 2 study of Epcoritamab as a consolidation therapy for 2nd generation BTKi +/- Obinutuzumab in CLL/SLL patients or patients with variants of this.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Cincinnati, Cincinnati, Ohio

   Run by

   Zulfa Omer

   See if you can join NCT07108998 on ClinicalTrials.gov

6. Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)

   Subjects on this study have a type of lymph gland cancer called Non-Hodgkin Lymphoma, acute lymphocytic leukemia, or chronic Lymphocytic Leukemia (these diseases will be referred to as "lymphoma" or "leukemia"). The lymphoma or leukemia has come back or has not gone away after treatment. The body h…

   Stage

   Phase 1

   Ages

   Up to 75

   Site

   Houston Methodist Hospital, Houston, Texas

   Locations

   2 in total

   Run by

   Baylor College of Medicine

   See if you can join NCT01853631 on ClinicalTrials.gov

7. Mosunetuzumab for CLL MRD Clearance

   The goal of this study is to test mosunetuzumab given alone or in combination with a Bruton tyrosine kinase inhibitor (BTKi, such as ibrutinib, acalabrutinib, zanubrutinib, or pirtobrutinib) in participants with CLL (chronic lymphocytic leukemia) or small lymphocytic lymphoma (SLL). The names of th…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Brigham & Women's Hospital, Boston, Massachusetts

   Locations

   2 in total

   Run by

   Inhye Ahn

   See if you can join NCT07052695 on ClinicalTrials.gov

8. AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

   This is an open-label, multi-center Phase 1b clinical study of oral AS-1763 (docirbrutinib) in patients with CLL/SLL or B-cell NHL who have failed or are intolerant to ≥2 lines of systemic therapy.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UC Irvine Health, Orange, California

   Locations

   13 in total

   Run by

   Carna Biosciences, Inc.

   See if you can join NCT05602363 on ClinicalTrials.gov

9. Effects of Nicotinamide in Patients With Chronic Lymphocytic Leukemia With History of Non-melanoma Skin Cancers

   This is a randomized, phase II, double-blind, placebo-controlled trial with planned crossover to the intervention arm after 1 year. Consenting patients with CLL who have had at least one NMSC diagnosed in the past year will be randomized to receive either oral nicotinamide 500 mg twice daily (BID) …

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Huntsman Cancer Institute at University of Utah, Salt Lake City, Utah

   Run by

   University of Utah

   See if you can join NCT04844528 on ClinicalTrials.gov

10. In Vivo Metabolic Profiling of CLL (Chronic Lymphocytic Leukemia)

    Metabolic reprogramming has been identified as a hallmark of cancer. Almost a century after Otto Warburg initially discovered increased glycolytic activity in tumor tissue ("Warburg effect"), therapeutic targeting of cancer metabolism has become a field of intense research effort in cancer biology.…

    Stage

    Not phased

    Ages

    18 and older

    Site

    University of Wisconsin, Madison, Wisconsin

    Run by

    University of Wisconsin, Madison

    See if you can join NCT04785989 on ClinicalTrials.gov

11. Long-term Follow-up Study of Patients Receiving CAR-T Cells

    This protocol is designed as a long-term follow-up study of participants who will receive CAR-T cells as part of a clinical trial at the Medical College of Wisconsin/ Froedtert Hospital. The clinical trials include the following: Phase 1 Study of CAR-20/19-T Cells in Patients with Relapsed Refracto…

    Stage

    Not phased

    Ages

    18 to 80

    Site

    Froedtert Hospital & Medical College of Wisconsin, Milwaukee, Wisconsin

    Run by

    Medical College of Wisconsin

    See if you can join NCT03375619 on ClinicalTrials.gov

12. Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

    This phase Ib trial tests the safety and effectiveness of tafasitamab, acalabrutinib, and obinutuzumab in treating patients with previously untreated chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). CLL and SLL are types of cancer that develops from a specific white blood ce…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    OHSU Knight Cancer Institute, Portland, Oregon

    Run by

    OHSU Knight Cancer Institute

    See if you can join NCT05943496 on ClinicalTrials.gov

13. Two Step Haplo With Radiation Conditioning

    This phase II clinical trial evaluates whether a modified modality of conditioning reduces treatment-related mortality (TRM) in patients who undergo a hematopoietic stem cell transplant (HSCT) for a hematological malignancy. HSCT is a curative therapy for many hematopoietic malignancies, however th…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadephia, Pennsylvania

    Run by

    Thomas Jefferson University

    See if you can join NCT05031897 on ClinicalTrials.gov

14. A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

    People who have chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) are often treated with ibrutinib, acalabrutinib, or zanubrutinib. These are pills that are taken by mouth. This type of pill is called "Bruton Tyrosine Kinase Inhibitor" or BTKi. Another treatment for CLL/SLL is …

    Stage

    Phase 2

    Ages

    18 to 80

    Site

    San Francisco VA Medical Center, San Francisco, CA, San Francisco, California

    Locations

    4 in total

    Run by

    VA Office of Research and Development

    See if you can join NCT06520098 on ClinicalTrials.gov

15. Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation

    This study evaluates the effectiveness and safety of Polatuzumab vedotin plus infusional chemoimmunotherapy containing rituximab, etoposide, prednisone, cyclophosphamide and hydroxydaunorubicin. This is a single arm study. Enrolled patients will receive up to six cycles (21-day cycles) of therapy. …

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Mount Sinai- Icahn School of Medicine, New York, New York

    Locations

    4 in total

    Run by

    Weill Medical College of Cornell University

    See if you can join NCT04679012 on ClinicalTrials.gov

16. Implanted Loop Recorders for Detection and Management of Arrhythmia With Bruton Tyrosine Kinase Inhibitors

    This study will enroll patients initiating Bruton Tyrosine Kinase (BTK) inhibitors without history of documented arrhythmia while on therapy using the Medtronic LINQ-2 insertable cardiac monitor (ILR). The incidence of new onset atrial fibrillation (AF) and other arrhythmia will be determined. Acti…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Northwell (Northshore University/Long Island Jewish Hospitals), New Hyde Park, New York

    Run by

    Northwell Health

    See if you can join NCT05643235 on ClinicalTrials.gov

17. Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment

    This study evaluates immune responses after CAR-T therapy to find out if CAR-T therapy reduces the effectiveness of the vaccines (vaccine immunity) against diseases such as measles, mumps and rubella, among others in patients with multiple myeloma and non-Hodgkin lymphoma.

    Stage

    Not phased

    Ages

    18 and older

    Site

    OHSU Knight Cancer Institute, Portland, Oregon

    Run by

    OHSU Knight Cancer Institute

    See if you can join NCT06784167 on ClinicalTrials.gov

18. LP-168 and Obinutuzumab for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Variants of This

    Multicenter Parallel 2 Cohort Phase 2 Study of LP-168 and Obinutuzumab for Previously Treated, and T474 Gatekeeper Mutant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Variants of This.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    University of Cincinnati Medical Center, Cincinnati, Ohio

    Run by

    Zulfa Omer

    See if you can join NCT06978088 on ClinicalTrials.gov

19. Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia

    This trial aims to demonstrate the feasibility of this approach to reliably generate product and to safely administer the product to patients who have B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia.

    Stage

    Phase 2

    Ages

    18 to 79

    Site

    AHN Cancer Institute - West Penn Hospital, Pittsburgh, Pennsylvania

    Run by

    John Lister

    See if you can join NCT05281809 on ClinicalTrials.gov

20. Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL

    This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, combined with acalabrutinib for the treatment of adults with Diffuse Large B-Cell Lymphoma and Chronic Lymphocytic Leukemia. Participants must be relapsed/refractory (having failed prior therapy)

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Goshen Center for Cancer Care, Goshen, Indiana

    Locations

    45 in total

    Run by

    Kartos Therapeutics, Inc.

    See if you can join NCT04502394 on ClinicalTrials.gov